basal ganglia disease: A disease involving the basal ganglia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
499 |
4. Check minimum number of eventsNone |
499 |
5. Include endpointsNone |
499 |
6. Filter based on genotype QC (FinnGen only) |
499 |
Control definitions (FinnGen only)
- Control exclude
- G6_XTRAPYR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G20-G26
- Name in latin
- Alii morbi degenerativi gangliorum basalium
Similar endpoints
↥List of similar endpoints to
Other degenerative diseases of the basal ganglia
based on the number of shared cases.
Similar with more cases:
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4228 | 1862 | 2313 |
| Only index persons | 3359 | 1496 | 1863 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.05 | 0.06 |
| Only index persons | 0.06 | 0.05 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 72.48 | 72.52 | 72.47 |
| Only index persons | 72.80 | 72.69 | 72.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 499 | 187 | 312 |
| Unadjusted period prevalence (%) | 0.11 | 0.06 | 0.14 |
| Median age at first event (years) | 72.45 | 70.30 | 73.74 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 434
- Matched controls
- 4337
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
746.1
323.0
307
14
G20
ICD-10 Finland
Parkinson disease
998.1
260.2
230
5
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
+∞
257.8
221
*
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
+∞
242.0
209
*
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
149.9
135
*
N87
ICPC
Parkinsonism
219.0
137.6
136
9
G23.8
ICD-10 Finland
Other specified degenerative diseases of basal ganglia
+∞
92.0
85
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
944.9
82.3
78
*
N04BD01
ATC
selegiline; oral
307.6
54.5
54
*
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
547.5
50.5
49
*
N04BC04
ATC
ropinirole; oral
175.1
45.8
47
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.9
41.7
103
164
N04BC05
ATC
pramipexole; oral
8.0
36.2
87
131
R25.1
ICD-10 Finland
Tremor, unspecified
19.5
36.0
55
32
L28
ICPC
Limited function/disability (L)
4.3
35.9
163
529
A28
ICPC
Limited function/disability NOS
4.4
35.5
157
495
R53
ICD-10 Finland
Malaise and fatigue
4.2
34.9
166
560
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
+∞
33.8
32
*
N04BD02
ATC
rasagiline; oral
352.4
33.4
33
*
G23.2
ICD-10 Finland
Multiple system atrophy, parkinsonian type [MSA-P]
+∞
30.6
29
*
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
12.7
27.7
50
44
SPAT1216
SPAT
Assessment of functional ability
3.7
27.6
145
515
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
149.2
26.9
28
*
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
+∞
26.3
25
*
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
+∞
26.3
25
*
SPAT1229
SPAT
Assessment of need for aid
4.9
26.3
94
231
N05AH04
ATC
quetiapine; oral
4.4
26.3
106
295
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.1
25.4
201
952
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.5
24.8
98
266
AA1AD
NOMESCO Finland
CT of head and brain
3.1
24.8
184
833
R4130
NOMESCO Finland
Speech therapy
13.5
24.6
43
35
193
Kela drug reimbursment
Rasagiline
+∞
24.2
23
*
R13
ICD-10 Finland
Dysphagia
5.6
23.5
73
152
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.3
22.7
136
521
N99
ICPC
Neurological disease other
19.3
22.6
34
19
G04BD12
ATC
mirabegron; oral
4.0
21.3
95
286
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.0
21.2
72
165
N04BC09
ATC
rotigotine; transdermal
+∞
21.0
20
*
N03AE01
ATC
clonazepam; systemic
6.3
21.0
58
104
N06DA03
ATC
rivastigmine; oral, transdermal
6.8
20.8
54
89
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
10.9
20.3
39
39
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.7
19.4
185
944
R47.1
ICD-10 Finland
Dysarthria and anarthria
21.3
19.3
28
14
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
19.2
130
535
G90.3
ICD-10 Finland
Multi-system degeneration
198.1
18.7
19
*
XA800
NOMESCO Finland
Neuropsychological investigation
7.6
18.7
44
63
N06AX11
ATC
mirtazapine; oral
2.7
18.2
168
833
H02AA02
ATC
fludrocortisone; oral
28.1
18.0
24
9
N04BX02
ATC
entacapone; oral
+∞
17.8
17
*
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
12.7
17.6
31
26
D21
ICPC
Swallowing problem
11.0
17.0
32
31
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.9
16.9
75
222
SPAT1231
SPAT
Assessment of adjustments needed in living environment
8.9
16.1
34
41
A04
ICPC
Weakness/tiredness general
3.3
15.8
87
305
TAB00
NOMESCO Finland
Lumbar puncture
6.0
15.4
43
78
A06AD11
ATC
lactulose; oral
2.9
15.3
106
433
N06AB10
ATC
escitalopram; oral
3.2
15.3
90
331
XF606
NOMESCO Finland
Ortostatic test
21.0
15.2
22
11
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.9
15.1
106
438
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
4.9
14.9
50
113
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.1
14.8
91
344
R42
ICD-10 Finland
Dizziness and giddiness
2.5
14.8
139
680
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
12.5
14.8
26
22
G23.3
ICD-10 Finland
Multiple system atrophy, cerebellar type [MSA-C]
+∞
14.7
14
*
I95.1
ICD-10 Finland
Orthostatic hypotension
5.5
14.4
43
85
JDB10
NOMESCO Finland
Percutaneous gastrostomy
12.6
14.3
25
21
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
4.5
14.2
52
128
G31.8
ICD-10 Finland
Other specified degenerative diseases of nervous system
44.0
14.2
17
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.1
13.6
37
65
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.5
13.6
40
78
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.2
13.2
51
133
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.8
13.2
58
170
SPAT1234
SPAT
Support of social functional capacity
4.7
13.0
45
105
N04AA02
ATC
biperiden; systemic
13.9
12.1
20
15
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.7
11.9
54
162
P20
ICPC
Memory disturbance
2.7
11.9
90
383
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.7
11.8
53
158
N19
ICPC
Speech disorder
9.3
11.4
23
26
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
10.0
11.4
22
23
R5110
SPAT
NA
6.9
11.1
27
41
R4110
NOMESCO Finland
Physiotherapy
2.1
10.5
141
799
R1250
NOMESCO Finland
Evaluation of functional capability
8.0
10.5
23
30
G21.1
ICD-10 Finland
Other drug-induced secondary parkinsonism
+∞
10.5
10
*
N29
ICPC
Neurological sympt/complt other
7.4
10.4
24
34
N04BB01
ATC
amantadine; oral
10.4
10.1
19
19
S01.0
ICD-10 Finland
Open wound of scalp
3.0
10.0
58
209
N28
ICPC
Limited function/disability (N)
9.9
9.9
19
20
G25.0
ICD-10 Finland
Essential tremor
9.9
9.9
19
20
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.9
9.5
61
233
TJD20
NOMESCO Finland
Change of gastrostomy tube
102.1
9.4
10
*
U04
ICPC
Incontinence urine
3.9
9.3
37
100
R1260
NOMESCO Finland
Evaluation of communicative skills
7.3
9.1
21
30
S06.0
ICD-10 Finland
Concussion
2.9
9.1
57
217
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
9.0
140
834
N30.0
ICD-10 Finland
Acute cystitis
2.5
8.9
73
323
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.4
8.9
31
74
N06AB04
ATC
citalopram; systemic
2.2
8.9
100
521
SPAT1294
SPAT
Other function in accordance with health social work nomenclature
5.7
8.7
24
44
G81.9
ICD-10 Finland
Hemiplegia, unspecified
16.7
8.6
13
8
W19
ICD-10 Finland
Unspecified fall
2.8
8.5
56
218
G25.2
ICD-10 Finland
Other specified forms of tremor
91.7
8.4
9
*
N03AG01
ATC
valproic acid; systemic, rectal
3.8
8.4
34
94
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.1
8.3
31
79
N05AH03
ATC
olanzapine; systemic
4.3
8.1
29
71
N05BA04
ATC
oxazepam; oral
2.0
8.1
113
640
M48.0
ICD-10 Finland
Spinal stenosis
2.3
8.1
80
388
N17
ICPC
Vertigo/dizziness
2.5
8.0
63
273
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
13.3
7.9
13
10
SPAT1245
SPAT
Provision of support and information to patient’s family members
3.3
7.9
39
127
M03BX01
ATC
baclofen; systemic
8.3
7.7
16
20
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.0
7.6
43
152
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.3
7.6
75
365
H50.52
ICD-10 Finland
Exophoria
13.7
7.4
12
9
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
9.6
7.3
14
15
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.3
7.3
36
117
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
+∞
7.3
7
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
+∞
7.3
7
*
G23.0
ICD-10 Finland
Hallervorden-Spatz disease
+∞
7.3
7
*
IGY99
NOMESCO Finland
Other psychiatric treatment contact
30.5
7.2
9
*
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
8.1
7.2
15
19
SPAT1254
SPAT
Administration of medicine
2.1
7.1
84
441
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
12.3
7.1
12
10
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.7
7.0
47
185
SPAT1053
SPAT
Memory test
2.0
6.9
99
561
C07AA05
ATC
propranolol; systemic
2.2
6.9
70
345
R41.3
ICD-10 Finland
Other amnesia
3.9
6.8
26
69
M54.5
ICD-10 Finland
Low back pain
1.8
6.8
129
812
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.1
6.7
20
41
K90
ICPC
Stroke/cerebrovascular accident
3.7
6.7
28
80
S01.41
ICD-10 Finland
Open wound in the temple-jaw region
8.9
6.6
13
15
K59.09
ICD-10 Finland
Constipation, unspecified
2.7
6.5
42
163
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.2
6.5
33
110
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
11.2
6.3
11
10
N04BC02
ATC
pergolide; oral
+∞
6.3
6
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
5.2
6.2
18
36
L02
ICPC
Back symptom/complaint
2.7
6.2
41
162
SPAT1244
SPAT
Occupational therapy
8.8
6.1
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
38
9.53
28.01
1.1
1.0
212.15
279.22
ng/l
1.39
20
23
34
38
9.53
28.01
1.1
1.0
601.20
518.52
ng/l
0.48
20
23
34
38
9.53
28.01
1.1
1.0
34.47
42.00
ng/l
0.53
17
23
49
84
6.36
27.99
1.3
1.3
2.44
103.96
e6/l
0.88
39
70
49
84
6.36
27.99
1.4
1.4
337.03
1611.28
e6/l
0.49
39
71
250
1380
2.63
24.66
2.6
2.2
214.20
280.47
u/l
0.44
239
1294
131
572
2.75
20.08
1.8
1.8
—
—
—
0
0
129
576
2.67
18.80
1.9
1.8
—
—
—
0
0
159
816
2.39
17.03
1.9
1.8
—
—
—
0
0
179
976
2.30
16.60
1.7
1.8
1153.41
1181.81
nmol/l
0.14
144
735
156
825
2.30
15.36
3.1
3.0
2.05
0.94
e6/l
0.56
84
491
288
2010
2.02
13.13
4.1
5.0
34.58
34.65
g/l
0.07
271
1872
20
31
6.68
12.46
1.0
1.2
—
6.77
nmol/l
—
0
5
276
1939
1.95
11.89
2.4
2.1
89.59
92.53
pmol/l
0.59
165
1006
206
1314
1.97
11.79
3.7
3.4
0.50
0.51
e6/l
0.05
159
1004
75
319
2.59
11.70
1.8
1.7
—
—
—
0
0
141
788
2.10
11.65
3.4
3.2
3.20
1.48
e6/l
0.96
70
458
66
273
2.63
10.87
1.5
1.5
—
—
—
0
0
307
2283
1.90
10.63
5.8
7.1
1.21
1.21
mmol/l
0.57
268
1925
290
2123
1.87
10.49
5.2
6.2
1.21
1.21
mmol/l
0.37
266
1906
244
1710
1.84
9.98
3.7
3.4
—
—
—
0
0
20
40
5.17
9.64
1.2
1.1
—
—
—
0
0
18
33
5.62
9.51
1.2
1.0
—
—
—
0
0
209
1438
1.78
8.76
3.8
3.5
49.14
120.51
e6/l
0.86
155
1128
220
1537
1.77
8.75
2.2
3.7
2.35
2.34
mmol/l
0.11
189
1329
128
761
1.92
8.57
2.0
3.4
0.83
0.81
mmol/l
0.90
117
713
273
2044
1.74
8.39
4.3
4.0
0.00
0.00
estimate
0.00
36
392
357
2924
1.78
7.61
3.6
3.7
15.27
15.05
pmol/l
0.85
325
2576
271
2066
1.68
7.45
4.4
4.0
0.00
0.00
estimate
0.00
37
377
13
23
5.78
7.10
1.1
1.0
—
—
—
0
0
266
2036
1.66
7.06
5.6
5.5
0.00
0.00
estimate
0.00
36
390
150
1001
1.71
6.64
2.6
2.7
4.75
4.28
e6/l
0.19
126
885
141
928
1.72
6.55
3.0
3.4
2.44
2.45
mmol/l
0.46
126
820
10
15
6.78
6.33
1.4
1.1
—
—
—
0
0
323
2660
1.61
5.88
5.2
5.0
6.50
6.85
mmol/l
3.07
305
2518
170
1208
1.62
5.78
1.7
1.6
17.06
19.92
nmol/l
2.30
158
1001
362
3073
1.65
5.75
3.6
4.2
13.40
14.25
mm/h
0.40
328
2790
242
1872
1.57
5.71
2.9
2.3
—
—
—
0
0
134
906
1.65
5.52
3.9
4.1
40.11
276.35
ng/l
3.96
113
783
407
3600
1.71
5.10
4.8
4.6
1.89
2.38
mu/l
0.78
373
3188
38
174
2.28
5.05
2.1
2.4
706.36
513.23
ug/l
0.15
33
169
33
143
2.40
4.96
1.2
1.2
—
—
—
0
0
440
3992
1.86
4.88
22.9
17.3
32.69
27.16
mg/l
2.46
401
3250
132
917
1.60
4.80
4.9
4.3
1.02
1.02
kg/l
0.55
20
141
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
20
5.08
4.79
1.3
1.1
—
—
—
0
0
0
111
0.00
4.44
0.0
3.6
—
371.25
—
0
103
59
338
1.85
4.31
1.5
1.7
—
—
—
0
0
0
108
0.00
4.25
0.0
2.0
—
2.72
—
0
82
374
3292
1.54
4.22
5.8
8.1
78.33
81.83
u/l
0.88
350
3056
73
458
1.70
3.92
2.5
3.2
120.52
215.32
ng/l
3.99
65
416
91
605
1.62
3.91
5.9
7.3
2.08
1.16
mmol/l
1.12
77
470
141
1038
1.50
3.86
1.6
1.8
430.62
6722126.71
pmol/l
0.50
117
848
75
1122
0.61
3.82
1.4
1.7
1.21
1.29
mmol/l
0.49
67
908
122
881
1.51
3.64
1.4
1.7
1.40
1.42
mg/l
0.01
93
703
106
745
1.54
3.58
1.3
1.2
2.57
1.38
u/ml
0.26
18
184
54
321
1.77
3.52
6.2
9.3
0.73
0.69
%
0.35
54
316
150
1139
1.45
3.46
5.2
4.2
0.00
0.00
estimate
0.00
37
364
158
1212
1.44
3.46
2.3
2.1
2.89
3.05
mg/l
0.38
132
1035
54
323
1.75
3.45
6.3
9.1
1.35
1.37
%
0.06
54
318
206
1662
1.41
3.39
1.9
2.2
77.85
79.46
nmol/l
0.30
170
1440
9
19
4.80
3.25
1.6
1.2
—
—
—
0
0
63
401
1.65
3.22
2.1
2.4
30.65
33.49
u/l
0.42
55
342
5
184
0.26
3.17
1.4
1.8
—
—
—
0
0
279
2391
1.38
3.11
8.0
9.4
4.32
4.22
e9/l
0.31
229
2102
83
572
1.54
3.05
10.3
8.4
—
—
—
0
0
107
780
1.47
3.01
1.7
1.9
29.76
29.91
s
0.11
102
751
19
82
2.37
2.95
1.3
1.1
—
—
—
0
0
8
17
4.76
2.93
1.0
1.5
30.00
30.53
umol/l
—
8
17
35
195
1.85
2.84
2.6
3.5
1.06
1.38
mmol/l
1.35
35
189
7
14
5.05
2.73
1.4
1.0
—
—
—
0
0
220
1847
1.34
2.66
4.6
4.1
38.35
42.80
ng/l
0.22
179
1452
65
438
1.56
2.65
1.8
3.1
65.02
65.51
g/l
0.21
58
390
5
7
7.20
2.55
1.2
1.0
—
—
—
0
0
39
235
1.72
2.47
3.3
4.2
25.18
23.94
mmol/l
1.04
33
215
6
12
5.05
2.41
1.2
1.1
—
—
—
0
0
6
12
5.05
2.41
1.2
1.1
—
—
—
0
0
6
12
5.05
2.41
1.2
1.1
—
—
—
0
0
200
1679
1.32
2.34
2.3
2.7
145.76
168.90
ug/l
0.95
182
1518
22
112
2.01
2.34
1.1
1.2
—
—
—
0
0
22
113
1.99
2.29
1.1
1.2
—
—
—
0
0
6
13
4.66
2.27
1.2
1.1
—
—
—
0
0
6
13
4.66
2.27
1.2
1.1
—
—
—
0
0
266
2330
1.30
2.26
4.2
6.7
11.16
12.24
umol/l
1.35
249
2205
273
2408
1.30
2.16
2.9
3.2
45.28
56.56
u/l
1.16
249
2195
19
97
2.00
2.03
1.5
1.3
—
—
—
0
0
19
97
2.00
2.03
1.5
1.3
—
—
—
0
0
445
4229
1.48
2.01
27.4
20.9
139.60
139.60
mmol/l
0.00
438
4110
65
466
1.45
2.00
2.1
2.0
0.20
0.21
g/l
0.11
57
434
52
360
1.50
1.91
2.0
4.1
74.30
91.74
ng/l
0.80
47
313
445
4237
1.46
1.91
27.5
21.0
3.94
4.02
mmol/l
7.56
437
4119
40
592
0.65
1.90
4.4
4.8
33.39
32.09
%
0.43
28
384
48
328
1.51
1.88
1.4
1.7
1.51
1.68
%
1.48
36
263
8
28
2.89
1.87
3.5
2.5
—
—
—
0
0
63
456
1.44
1.85
2.1
2.7
9.35
6.85
ug/l
0.38
52
406
25
147
1.74
1.77
1.1
1.3
—
—
—
0
0
366
3399
1.29
1.73
26.7
19.1
38.09
38.64
%
0.54
225
2132
64
472
1.41
1.71
3.6
3.8
2.58
1.93
mmol/l
0.48
55
374
31
196
1.62
1.70
2.2
2.8
7.05
7.46
g/l
0.55
26
141
31
196
1.62
1.70
2.2
2.8
3.79
3.81
g/l
0.02
26
136
31
196
1.62
1.70
2.2
2.8
—
—
—
0
0
369
3919
0.78
1.68
4.3
4.9
4.27
4.42
mmol/l
2.10
336
3557
89
696
1.34
1.67
30.2
28.2
1.51
1.31
inr
—
9
88
34
222
1.57
1.64
2.0
1.9
1.35
2.89
ug/l
0.52
24
195
12
56
2.17
1.62
2.7
4.2
—
—
—
0
0
182
1569
1.25
1.61
5.1
4.3
—
—
—
0
0
366
3881
0.79
1.55
4.1
4.9
1.39
1.43
mmol/l
1.17
329
3479
7
28
2.52
1.45
1.1
1.3
—
—
—
0
0
7
28
2.52
1.45
1.1
1.3
—
—
—
0
0
11
52
2.14
1.45
2.4
2.8
—
—
—
0
0
160
1376
1.24
1.42
2.6
2.4
54.76
57.34
u/l
0.55
143
1269
5
120
0.41
1.39
1.6
2.9
1.43
1.76
mg/l
—
5
109
17
97
1.78
1.36
1.2
1.5
—
—
—
0
0
0
37
0.00
1.35
0.0
1.2
—
85.40
—
0
5
0
37
0.00
1.35
0.0
1.3
—
—
—
0
0
51
379
1.38
1.34
1.9
2.0
401.53
380.51
nmol/l
0.39
45
345
20
121
1.68
1.32
1.5
1.5
188.50
255.91
ug/g
—
10
67
65
504
1.33
1.31
2.3
2.6
6.36
9.28
umol/l
1.64
55
450
219
1963
1.21
1.27
4.4
5.5
57.92
58.44
%
0.22
201
1829
125
1059
1.24
1.27
2.4
2.6
—
—
—
0
0
14
77
1.84
1.26
1.6
1.3
—
—
—
0
0
222
1996
1.20
1.24
4.6
5.7
25.48
26.07
%
0.29
201
1839
356
3754
0.82
1.20
3.8
4.4
1.19
1.25
mmol/l
1.29
319
3347
0
34
0.00
1.16
0.0
1.2
—
—
—
0
0
147
1278
1.21
1.16
2.5
3.3
29.68
33.06
u/l
0.84
134
1216
222
2013
1.19
1.10
4.5
4.2
—
—
—
0
0
5
22
2.29
1.03
2.8
2.5
71.20
83.73
nmol/l
—
5
22
191
1722
1.18
0.99
4.3
4.8
19.88
21.35
%
0.86
89
912
0
29
0.00
0.98
0.0
1.2
—
—
—
0
0
0
29
0.00
0.98
0.0
1.2
—
—
—
0
0
0
29
0.00
0.98
0.0
1.2
—
—
—
0
0
0
31
0.00
0.96
0.0
1.0
—
—
—
0
0
9
51
1.78
0.95
1.0
1.3
0.58
0.57
nmol/l
—
9
45
6
27
2.24
0.93
1.5
1.1
—
—
—
0
0
6
27
2.24
0.93
1.8
1.7
—
—
—
0
0
387
4020
0.83
0.92
5.0
5.5
2.44
2.56
mmol/l
1.99
351
3612
12
72
1.68
0.86
1.2
1.3
—
—
—
0
0
33
251
1.34
0.80
1.3
2.2
1.41
1.52
g/l
0.33
28
221
8
48
1.68
0.79
1.4
1.5
—
—
—
0
0
445
4335
1.25
0.79
33.0
25.5
239.41
236.89
e9/l
0.36
432
4206
14
90
1.57
0.79
1.6
1.6
—
—
—
0
0
445
4337
1.24
0.77
33.0
25.4
4.31
4.42
e12/l
4.39
431
4187
445
4337
1.24
0.77
33.2
25.6
129.48
133.80
g/l
7.53
438
4247
0
28
0.00
0.76
0.0
1.2
—
—
—
0
0
0
28
0.00
0.76
0.0
1.2
—
—
—
0
0
46
564
0.80
0.74
2.7
4.6
2.68
35.67
ug/l
1.62
34
485
83
716
1.19
0.72
2.0
2.5
2.13
2.25
g/l
1.06
76
664
12
76
1.59
0.72
2.4
1.7
—
—
—
0
0
5
26
1.93
0.71
1.6
1.3
—
—
—
0
0
12
180
0.66
0.69
3.5
3.9
—
2.20
—
0
16
334
3195
1.14
0.67
27.6
21.4
13.80
13.88
%
0.56
329
3133
37
296
1.27
0.66
3.6
3.7
3.26
2.08
mmol/l
1.09
25
225
26
199
1.32
0.63
1.8
1.9
—
—
—
0
0
24
182
1.33
0.62
1.8
1.7
—
—
—
0
0
88
775
1.16
0.61
2.0
2.5
10.47
12.40
umol/l
2.47
78
717
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
2.4
—
—
—
0
0
0
20
0.00
0.60
0.0
2.4
—
—
—
0
0
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
305.00
—
0
12
0
21
0.00
0.60
0.0
2.3
—
—
—
0
0
8
55
1.46
0.56
1.3
1.5
—
—
—
0
0
8
122
0.65
0.55
3.0
2.2
8.29
7.61
kpa
—
8
107
226
2135
1.11
0.52
4.6
5.6
4.57
2.93
ug/l
0.31
197
1878
134
1238
1.11
0.47
2.8
3.3
0.54
0.78
ug/l
4.29
102
880
7
49
1.43
0.46
1.0
1.4
—
—
—
0
0
10
140
0.71
0.44
2.2
2.5
26.76
25.07
mmol/l
—
10
116
5
31
1.62
0.43
1.2
1.3
—
—
—
0
0
8
57
1.41
0.42
1.3
1.5
—
—
—
0
0
8
57
1.41
0.42
1.3
1.5
—
—
—
0
0
8
57
1.41
0.42
1.3
1.5
—
—
—
0
0
8
57
1.41
0.42
1.3
1.5
—
—
—
0
0
76
684
1.13
0.42
2.2
2.5
19.52
22.18
%
1.18
62
588
8
58
1.39
0.41
1.3
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
5
34
1.48
0.40
2.0
1.6
—
—
—
0
0
387
3954
0.91
0.39
4.9
5.2
6.02
6.10
mmol/l
0.72
342
3531
33
386
0.84
0.38
3.4
3.9
1.24
1.22
mmol/l
0.91
26
339
8
115
0.69
0.37
1.6
1.3
—
—
—
0
0
25
297
0.83
0.35
1.3
1.4
—
—
—
0
0
144
1525
0.92
0.34
3.0
4.1
5.93
10.06
mg/mmol
0.97
103
976
11
144
0.76
0.33
1.4
1.6
—
156.67
—
0
6
56
503
1.13
0.33
5.4
3.5
—
—
—
0
0
6
87
0.69
0.33
1.0
1.2
64.23
38.88
u/l
—
6
72
6
88
0.68
0.33
1.0
1.3
—
—
—
0
0
6
46
1.31
0.33
3.5
2.5
2.72
6.82
nmol/l
—
6
46
6
89
0.67
0.33
1.2
1.7
42.00
45.64
nmol/l
—
6
81
54
600
0.89
0.33
1.2
1.3
15.48
39.37
iu/ml
2.81
13
180
6
47
1.28
0.32
1.3
1.3
—
—
—
0
0
38
430
0.87
0.30
1.4
1.3
—
—
—
0
0
14
111
1.27
0.30
1.4
2.1
79.86
84.62
%
0.39
14
106
18
148
1.22
0.29
1.1
1.0
—
—
—
0
0
8
63
1.27
0.28
1.6
1.5
—
—
—
0
0
8
64
1.25
0.27
1.5
1.6
—
—
—
0
0
12
149
0.80
0.26
1.7
3.0
189.25
78.43
u/ml
0.30
12
142
10
126
0.79
0.24
1.6
1.4
—
—
—
0
0
10
79
1.27
0.22
1.4
1.6
—
—
—
0
0
378
3837
0.94
0.22
6.0
6.7
39.30
40.99
mmol/mol
3.52
340
3503
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
2.58
—
0
5
0
12
0.00
0.21
0.0
2.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
110.08
—
0
12
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
5
43
1.16
0.21
1.4
1.1
—
—
—
0
0
427
4223
1.08
0.21
10.1
11.6
21.81
24.97
u/l
2.44
409
4034
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
6
50
1.20
0.19
1.8
1.5
—
—
—
0
0
12
143
0.84
0.19
2.3
1.6
—
—
—
0
0
31
341
0.90
0.18
3.2
3.2
63.00
58.21
ml/min/173m2
—
9
144
61
573
1.07
0.17
3.2
4.3
228.50
248.65
u/l
1.02
56
542
8
68
1.18
0.16
1.5
1.6
—
—
—
0
0
8
71
1.13
0.16
1.6
1.1
—
—
—
0
0
8
73
1.10
0.15
4.9
3.3
62.50
58.68
%
—
8
73
9
82
1.10
0.15
1.6
1.8
—
—
—
0
0
9
106
0.85
0.13
1.3
1.4
—
—
—
0
0
54
569
0.94
0.12
1.2
1.3
1.46
12.50
u/ml
3.21
17
205
376
3797
0.96
0.12
20.0
16.4
78.26
73.13
ml/min/173m2
5.64
319
3161
5
46
1.09
0.09
1.0
1.9
—
—
—
0
0
5
46
1.09
0.09
1.0
1.9
—
—
—
0
0
5
46
1.09
0.09
1.0
1.9
—
—
—
0
0
165
1618
1.03
0.09
2.7
3.1
936.17
1673.42
ng/l
3.44
149
1413
17
186
0.91
0.09
2.1
2.8
—
—
—
0
0
12
132
0.91
0.06
1.6
1.3
—
—
—
0
0
142
1442
0.98
0.06
2.6
3.2
8.09
7.34
mmol/l
1.11
118
1158
118
1194
0.98
0.03
2.3
3.0
4258.87
9437.08
umol/l
0.63
98
1003
11
116
0.95
0.00
1.5
1.6
—
—
—
0
0
18
177
1.02
0.00
1.2
1.1
103.78
137.32
iu/ml
—
6
61
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
183
0.98
0.00
2.8
2.4
0.36
0.34
u/ml
—
9
107
14
142
0.99
0.00
1.5
1.8
—
—
—
0
0
11
111
0.99
0.00
1.1
1.5
—
—
—
0
0
11
111
0.99
0.00
1.5
1.7
—
—
—
0
0
12
121
0.99
0.00
1.3
1.7
—
—
—
0
0
13
131
0.99
0.00
2.8
2.6
47.10
118.70
ug/min
—
7
76
5
49
1.02
0.00
1.0
2.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
7
0.00
0.00
0.0
1.1
—
94.71
—
0
7
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
0.00
0.0
1.1
—
174.29
—
0
7
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
70.20
—
0
5
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
6
60
1.00
0.00
1.7
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
80
1.00
0.00
4.0
2.8
105.75
105.51
mmol/l
—
8
80
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
91
0.99
0.00
1.3
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
83.83
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
3.6
—
13.23
—
0
9
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_BASDEGENOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 5.541 [4.56, 6.72] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.285 |
During the follow-up period (1.1.1998 — 31.12.2019), 710 out of 1242 females with G6_BASDEGENOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_BASDEGENOTH | 4.925 [3.86, 6.29] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 960 out of 1580 males with G6_BASDEGENOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_BASDEGENOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.511% | 0.88% |
| 5 | 3.368% | 5.096% |
| 10 | 8.029% | 12.307% |
| 15 | 14.69% | 22.676% |
| 20 | 24.56% | 35.996% |
Relationships between endpoints
↥Index endpoint: G6_BASDEGENOTH – Other degenerative diseases of the basal ganglia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data